Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Huntington's Disease Clear all

Conditions: Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sherman Oaks, California

Conditions: Huntington Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Alamitos, California • Englewood, Colorado + 10 more

Conditions: Huntington's Disease
Interventions: Minocycline; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Huntington's Disease
Interventions: Physical Activity Coaching; Other
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Cachexia
Interventions: In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Huntington Disease
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 25 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Davis, California • San Diego, California • Englewood, Colorado + 22 more

Conditions: Chorea, Huntington
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 27 more

Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions: Biological Sample Collection; Other
Lead sponsor: New York Stem Cell Foundation Research Institute; Other
Eligibility: 30 Days and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2045
U.S. locations: 1
States / cities: New York, New York

Conditions: Huntington Disease
Interventions: SKY-0515, SKY-0515 Placebo; Drug
Lead sponsor: Skyhawk Therapeutics, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more

Conditions: Chorea, Huntington's Disease
Interventions: Amantadine; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Huntingtons Disease
Interventions: RO7234292, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more

Conditions: Chorea, Huntington
Interventions: Valbenazine, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Huntington Disease
Interventions: Nilotinib 150 MG; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Huntington's Disease
Interventions: OMS643762, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more

Conditions: Huntington's Disease
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more

Conditions: HDL
Interventions: CardioLux™HDL, Placebo; Dietary Supplement
Lead sponsor: Metagenics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Huntington Disease
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 23 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Huntington Disease
Interventions: Dimebon, Placebo; Drug · Other
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 24
States / cities: Scottsdale, Arizona • Davis, California • Irvine, California + 21 more

Conditions: Huntington's Disease
Interventions: WVE-120102, Placebo; Drug
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: La Jolla, California • Sacramento, California • Boston, Massachusetts + 2 more

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: CHDI Foundation, Inc.; Other
Eligibility: 25 Years to 55 Years
Enrollment: 255 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Huntington Disease
Interventions: SPK-10001, Placebo Surgery Control; Genetic · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 5
States / cities: Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Minocycline in Patients With Huntington's Disease

Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD

Electronic-health Application To Measure Outcomes REmotely Clinical Trial

Genetic Risk: Whether, When, and How to Tell Adolescents

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NYSCF Scientific Discovery Biobank

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Treatment of Huntington's Chorea With Amantadine

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

Nilotinib in Huntington's Disease

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Oral Nutritional Supplement Effect on HDL Function

Pridopidine Phase 3 Study in Huntington's Disease

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Cognitive Assessment Battery (CAB) Beta Study

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD